Skip to main content
SpringerLink
Log in

Comparison of the relative toxicity of travoprost 0.004% without benzalkonium chloride and latanoprost 0.005% in an immortalized human cornea epithelial cell culture system

  • Published:
Advances in Therapy Aims and scope Submit manuscript

Abstract

The purpose of this study was to compare the relative toxicity of a new topical ophthalmic glaucoma medication, travoprost 0.004% without benzalkonium chloride (BAK), with that of commercially available latanoprost 0.005% (preserved with 0.02% BAK) in immortalized human corneal epithelial cells (HCEs). Tissue culture plates (96 well) containing HCEs were divided into 6 groups. Two groups served as negative controls (70% methanol and gentamicin). Another 2 groups—1 in corneal epithelial culture media and the other in a hydroxypropyl (HP)-Guar gellable lubricant eyedrop—served as live controls. The travoprost 0.004% without BAK and latanoprost 0.005% groups were exposed to 100 μL of the undiluted solutions. Cells were incubated for 25 min at 37°C. A live/dead assay was used to measure the effects of travoprost without BAK and of latanoprost on HCEs compared to 70% methanol and culture medium. Between the 2 glaucoma medications tested, travoprost 0.004% preserved without BAK showed significantly less toxicity on HCEs than did latanoprost 0.005%. This difference may have ramifications in terms of tolerability for patients who use these topical glaucoma drugs on a long-term basis.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Quigley HA, Broman AT. The number of people with glaucoma worldwide in 2010 and 2020.Br J Ophthalmol. 2006;90:262–267.

    Article  PubMed  CAS  Google Scholar 

  2. The AGIS Investigators. The advanced glaucoma intervention study (AGIS): 7. The relationship between control of intraocular pressure and visual field deterioration.Am J Ophthalmol. 2000;130: 429–440.

    Article  Google Scholar 

  3. Abelson MB, Washburn S. Review of Ophthalmology [serial online] 2002;9(05). Available at: http://www.revophth.com/index.asp?page=1_97.htm. Accessed on 6/18/06.

  4. Noecker R. Review of Ophthalmology [serial online] 2001 June. Available at: http://www. revophth.com/2001/june/cme0601_article.htm. Accessed on 6/18/06.

  5. Ishibashi T, Yokoi N, Kinoshita S. Comparison of the short-term effects on the human corneal surface of topical timolol maleate with and without benzalkonium chloride.J Glaucoma. 2003; 12:486–490.

    Article  PubMed  Google Scholar 

  6. Baudouin C, deLunardo C. Short term comparative study of topical 2% carteolol with and without benzalkonium chloride in healthy volunteers.Br J Ophthalmol. 1998;82:39–42.

    Article  PubMed  CAS  Google Scholar 

  7. Ubels JL, McCartney MD, Lantz WK, Beaird J, Dayalan A, Edelhauser HF. Effects of preservative-free artificial tear solutions on corneal epithelial structure and function.Arch Ophthalmol. 1995; 113:371–378.

    PubMed  CAS  Google Scholar 

  8. DeSaint JM, Debbasch C, Brignole F, Rat P, Warnet J-M, Baudouin C. Toxicity of preserved and unpreserved antiglaucoma topical drugs in an in vitro model of conjunctival cells.Current Eye Res. 2000;20:85–94.

    Article  Google Scholar 

  9. Cha SH, Lee J-S, Oum B-S, Kim C-D. Corneal epithelial cellular dysfunction from benzalkonium chloride (BAC) in vitro.Clin Exp Ophthalmol. 2004;32:180–184.

    Article  Google Scholar 

  10. Kass MA, Heuer DK, Higginbotham EJ, et al. The ocular hypertension treatment study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open angle glaucoma.Arch Ophthalmol. 2002;120:701–713.

    PubMed  Google Scholar 

  11. Pisella PJ, Pouliquen P, Baudouin C. Prevalence of ocular symptoms and signs with preserved and preservative free glaucoma medication.Br J Ophthalmol. 2002;86:418–423.

    Article  PubMed  CAS  Google Scholar 

  12. Yee RW, Sorour HM, Yee SB, et al. Comparison of relative toxicity of four ophthalmic antibiotics using the human cornea epithelial cell culture system.Invest Ophthalmol Vis Sci. 2004;45(suppl): 4939.

    Google Scholar 

  13. Baudouin C, Hamard P, Liang H, Creuzot-Garcher C, Bensoussan L, Brignole F. Conjunctival epithelial cell expression of interleukins and inflammatory markers in glaucoma patients treated over the long term.Ophthalmology. 2004;111:2186–2192.

    Article  PubMed  Google Scholar 

  14. Debbasch C, Brignole F, Pisella PJ, Warnet JM, Rat P, Baudouin C. Quaternary ammoniums and other preservatives’ contribution in oxidative stress and apoptosis on Chang conjunctival cells.Invest Ophthalmol Vis Sci. 2001;42:642–652.

    PubMed  CAS  Google Scholar 

  15. Broadway DC, Grierson I, O’Brien C, Hitchings RA. Adverse effects of topical antiglaucoma medication. I. The conjunctival cell profile.Arch Ophthalmol. 1994;112:1437–1445.

    PubMed  CAS  Google Scholar 

  16. Broadway DC, Grierson I, O’Brien C, Hitchings RA. Adverse effects of topical antiglaucoma medication. II. The outcome of filtration surgery.Arch Ophthalmol. 1994;112:1446–1454.

    PubMed  CAS  Google Scholar 

  17. Lavin MJ, Wormald RPL, Migdal CS, Hitchings RA. The influence of prior therapy on the success of trabeculectomy.Arch Ophthalmol. 1990;108:1543–1548.

    PubMed  CAS  Google Scholar 

  18. Johnson DH, Yoshikawa K, Brubaker RF, Hodge DO. The effect of long-term medical therapy on the outcome of filtration surgery.Am J Ophthalmol. 1994;117:139–148.

    PubMed  CAS  Google Scholar 

  19. Data on file. Alcon Laboratories, Inc., Market Research, 2006.

  20. Bielory L. Ocular allergy and dry eye syndrome.Curr Opin Allergy Clin Immunol. 2004;4:421–424.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Ophthalmology Hermann Eye Center, University of Texas Health Science Center at Houston, Houston, Texas

    Richard W. Yee MD, Evan G. Norcom BS & Xinping C. Zhao PhD

Authors
  1. Richard W. Yee MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Evan G. Norcom BS
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Xinping C. Zhao PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Yee, R.W., Norcom, E.G. & Zhao, X.C. Comparison of the relative toxicity of travoprost 0.004% without benzalkonium chloride and latanoprost 0.005% in an immortalized human cornea epithelial cell culture system. Adv Therapy 23, 511–518 (2006). https://doi.org/10.1007/BF02850039

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02850039

Keywords

Search

Navigation